Skip to content

Mark Rus

Epix Pharmaceuticals (United States)

1 paper in the library · 162 citations · publishing 2021

Papers

Psychedelics and Other Psychoplastogens for Treating Mental Illness

Frontiers in Psychiatry October 4, 2021 Maxemiliano V. Vargas, Retsina Meyer, Arabo A. Avanes et al. 162 citations

Psychedelics, part of a broader class called psychoplastogens, promote structural and functional neural plasticity in brain circuits relevant to mental health. They produce lasting therapeutic effects after a single dose and show promise for depression, PTSD, anxiety, and substance use disorders. A theoretical framework explains their broad efficacy. Challenges like scalability and hallucinogenic effects may be addressed by non-hallucinogenic psychoplastogens. This shift in neuropsychiatry aims to cure mental illness by repairing underlying pathophysiology, not just treating symptoms.